These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35305699)

  • 1. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
    Isa F; Gonzalez Ortiz AM; Meyer J; Hamilton JD; Olenchock BA; Brackin T; Ganguly S; Forleo-Neto E; Faria L; Heirman I; Marovich M; Hutter J; Polakowski L; Irvin SC; Thakur M; Hooper AT; Baum A; Petro CD; Fakih FA; McElrath MJ; De Rosa SC; Cohen KW; Williams LD; Hellman CA; Odeh AJ; Patel AH; Tomaras GD; Geba GP; Kyratsous CA; Musser B; Yancopoulos GD; Herman GA;
    Lancet Infect Dis; 2024 Sep; ():. PubMed ID: 39236733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
    Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
    EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.
    Gütlin Y; Albertos Torres D; Gensch A; Schlotterbeck AK; Stöger L; Heller S; Infanti L; Barut GT; Thiel V; Leuzinger K; Hirsch HH; Buser A; Egli A
    Swiss Med Wkly; 2024 Jul; 154():3408. PubMed ID: 39137369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study.
    Kim WJ; Choi SH; Park JY; Song JS; Chung JW; Choi ST
    Ann Rheum Dis; 2022 Nov; 81(11):1585-1593. PubMed ID: 35878999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.
    Honda-Okubo Y; Antipov A; Andre G; Barati S; Kafi H; Petrovsky N
    Immunology; 2023 Oct; 170(2):193-201. PubMed ID: 37199229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
    Souza WM; Amorim MR; Sesti-Costa R; Coimbra LD; Brunetti NS; Toledo-Teixeira DA; de Souza GF; Muraro SP; Parise PL; Barbosa PP; Bispo-Dos-Santos K; Mofatto LS; Simeoni CL; Claro IM; Duarte ASS; Coletti TM; Zangirolami AB; Costa-Lima C; Gomes ABSP; Buscaratti LI; Sales FC; Costa VA; Franco LAM; Candido DS; Pybus OG; de Jesus JG; Silva CAM; Ramundo MS; Ferreira GM; Pinho MC; Souza LM; Rocha EC; Andrade PS; Crispim MAE; Maktura GC; Manuli ER; Santos MNN; Camilo CC; Angerami RN; Moretti ML; Spilki FR; Arns CW; Addas-Carvalho M; Benites BD; Vinolo MAR; Mori MAS; Gaburo N; Dye C; Marques-Souza H; Marques RE; Farias AS; Diamond MS; Faria NR; Sabino EC; Granja F; Proença-Módena JL
    Lancet Microbe; 2021 Oct; 2(10):e527-e535. PubMed ID: 34258603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
    Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
    Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
    Basile K; Rockett RJ; McPhie K; Fennell M; Johnson-Mackinnon J; Agius JE; Fong W; Rahman H; Ko D; Donavan L; Hueston L; Lam C; Arnott A; Chen SC; Maddocks S; O'Sullivan MV; Dwyer DE; Sintchenko V; Kok J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.